

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, Maryland
March 7, 2018

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Lauren D. Tesh, PharmD, BCPS

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Susan Halabi, PhD

Professor of Biostatistics and Bioinformatics
Duke University Medical Center
Durham, North Carolina

Philip C. Hoffman, MD

Professor of Medicine
The University of Chicago
Section of Hematology/Oncology
Department of Medicine
Chicago, Illinois

Grzegorz S. Nowakowski, MD

Associate Professor of Medicine and Oncology
Mayo Clinic Rochester
Rochester, Minnesota

Vassiliki A. Papadimitrakopoulou, MD

Professor of Medicine
The University of Texas MD Anderson Cancer Center
Department of Thoracic Head & Neck Medical
Oncology
Division of Cancer Medicine
Houston, Texas

Courtney J. Preusse, MA

(Consumer Representative)
Senior Research Administrator and CLIA
Operations Director
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Bruce J. Roth, MD

(Chairperson)
Professor of Medicine
Division of Oncology
Washington University School of Medicine
St. Louis, Missouri

ACTING INDUSTRY REPRESENTATIVE (Non-Voting)

Gary Gordon, MD, PhD

(Acting Industry Representative)
Vice President, Oncology Development
AbbVie, Inc.
North Chicago, Illinois

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
March 7, 2018

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Catherine Bollard, MD, FRACP, FRCPA

Bosworth Chair for Cancer Biology
Director, Center for Cancer and Immunology
Research
Professor of Pediatrics and Microbiology,
Immunology and Tropical Medicine
Children's National Health System
The George Washington University
School of Medicine and Health Sciences
Washington, District of Columbia

Arthur Flatau, PhD

(Patient Representative)
Austin, Texas

Christopher S. Hourigan, DPhil, FACP

Chief, Myeloid Malignancies
National Heart, Lung and Blood Institute
National Institutes of Health
Bethesda, Maryland

Andy Chen, MD PhD

Leader, Lymphoma Program
Knight Cancer Institute
Oregon Health & Science University
Portland, Oregon

David Harrington, PhD, MA

Professor of Statistics and Biostatistics
Dana-Farber Cancer Institute
Harvard T.H. Chan School of Public Health
Boston, Massachusetts

Anthony D. Sung, MD

Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular
Therapy
Duke University
Durham, North Carolina

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence, FDA
Acting Director, Office of Hematology & Oncology
Products (OHOP)
Office of New Drugs (OND), CDER, FDA

Donna Przepiorka, MD, PhD

Cross-Discipline Team Leader
DHP, OHOP, OND, CDER, FDA

Qing Xu, PhD

Statistical Reviewer
Division of Biometrics V
Office of Biostatistics
Office of Translational Sciences, CDER, FDA

Ann T. Farrell, MD

Director
Division of Hematology Products (DHP)
OHOP, OND, CDER, FDA

Emily Jen, MD, PhD

Clinical Reviewer
DHP, OHOP, OND, CDER, FDA